BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
Manufacturer: Orexo US, Inc.
Score: 141.0
Zubsolv is a sublingual tablet formulation of buprenorphine and naloxone used for the treatment of opioid dependence. It is indicated for use as part of a complete treatment plan that includes counseling and psychosocial support. The medication works by reducing withdrawal symptoms and cravings for opioids, allowing patients to manage their addiction. Key clinical findings indicate that Zubsolv is effective in reducing opioid use and improving treatment outcomes. Important safety information includes the risk of addiction, abuse, and misuse, as well as potential interactions with other medications. Contraindications include hypersensitivity to buprenorphine or naloxone, and the medication should be used with caution in patients with certain medical conditions. The recommended initial dose is up to 5.7 mg/1.4 mg on the first day, with adjustments made as needed to achieve a target dose of 11.4 mg/2.9 mg. Special population considerations include use during pregnancy, nursing mothers, pediatric use, and geriatric use.
Risk of addiction, abuse, and misuse
Dose adjustments may be necessary in patients with hepatic impairment or those taking other medications that interact with Zubsolv
Up to 5.7 mg/1.4 mg on the first day, with adjustments made as needed to achieve a target dose of 11.4 mg/2.9 mg